{
  "weights": {
    "clinical": 1.3,
    "dilution": 2.24,
    "fda": 1.4,
    "going_concern": 1.0,
    "partnership": 2.15,
    "uplisting": 1.3,
    "compliance_extension": 1.2,
    "delisting_relief": 1.3,
    "compliance_restored": 1.4,
    "extension_granted": 1.2,
    "energy_discovery": 1.15,
    "advanced_therapies": 1.25,
    "tech_contracts": 1.35,
    "dilution_risk": 2.5,
    "management_change": 2.49,
    "capital_raise": 2.39,
    "atm": 2.31,
    "offering": 2.22,
    "public_offering": 2.18,
    "distress_negative": 2.5,
    "executive_compensation": 2.5,
    "stock_offering": 2.5,
    "regulation_fd_disclosure": 2.2,
    "discounted_offering": 2.5,
    "secondary_offering": 2.37,
    "going_concern_warning": 2.28,
    "earnings_miss": 2.25,
    "warrant": 2.22,
    "registered_direct": 2.2,
    "agreement": 2.2,
    "material_agreement": 2.18,
    "equity_offering": 2.17,
    "reverse_stock_split": 2.5,
    "investor_presentation": 2.2,
    "potential_dilution": 2.44,
    "need_for_capital": 2.54,
    "earnings_beat": 2.21,
    "dilution_potential": 2.19,
    "share_offering": 2.19,
    "dividend_declaration": 2.17,
    "collaboration": 2.15,
    "at_the_market_offering": 2.14,
    "board_appointment": 2.13,
    "acquisition": 2.5,
    "earnings": 2.35,
    "unknown": 2.39,
    "beat": 2.23
  },
  "last_updated": "2025-12-09T04:45:00.000000+00:00",
  "source": "claude_manual_tuning",
  "total_keywords": 47,
  "updates_applied": 8,
  "min_confidence_threshold": 0.6,
  "tuning_notes": "Increased positive catalyst weights: tech_contracts (0.6->1.35), advanced_therapies (0.65->1.25), energy_discovery (0.75->1.15), clinical (1.0->1.3), fda (1.0->1.4), uplisting (1.0->1.3). Decreased overly harsh negatives: investor_presentation (2.8->2.2), regulation_fd_disclosure (2.8->2.2)"
}